Medacta Group (MOVE) H2 2024 earnings summary

Executive summary

• FY 2024 revenue reached EUR 590.6 million, up 16.2% in constant currency, marking the fifth consecutive year of strong growth and outperforming the market.

• Net profit increased by 53.9% to EUR 72.9 million; proposed dividend of CHF 0.69 per share, up 25.5% year-over-year.

• Adjusted EBITDA rose 19.4% to EUR 160.2 million, with a margin of 28%.

• Growth driven by innovation, expanded sales force, surgeon education, and strong performance across all geographies and business lines.

Financial highlights

• Gross profit reached EUR 399.4 million, up 14.8% year-over-year, with a gross margin of 67.6%.

• Operating cash flow increased 42% to EUR 107.1 million, supporting EUR 98.9 million in CapEx and generating EUR 8.3 million in free cash flow.

• Basic EPS rose to EUR 3.66 from EUR 2.37, up approximately 54%.

• Leverage remained low at 0.99x EBITDA.

Outlook and guidance

• 2025 revenue growth targeted at 13–15% in constant currency, with adjusted EBITDA margin around 27%, including the Parcus acquisition.

• Midterm outlook expects low double-digit CAGR and EBITDA margin in line with 2024 levels.

• Guidance incorporates Parcus acquisition and assumes normalization of market growth.